{"id":959516,"date":"2026-05-07T06:48:39","date_gmt":"2026-05-07T10:48:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/"},"modified":"2026-05-07T06:48:39","modified_gmt":"2026-05-07T10:48:39","slug":"biontech-announces-new-ads-repurchase-program-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/","title":{"rendered":"BioNTech Announces New ADS Repurchase Program"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <b>MAINZ, Germany,\u00a0May 7, 2026 (GLOBE NEWSWIRE)<\/b> &#8212;\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FdD0Pb2U41m0CeTKzIzVwp4Adj5QGep8zeVv0Iu9cYzE22LgKMt1GB3swWYftsSe9h4iuQoI7QZr9wlEnZb2M0-pFbSCV3HOx1EN1rEZ42miOZU064T045ALLp3nOo4L\" rel=\"nofollow\" target=\"_blank\">BioNTech SE<\/a> (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today announced that it has authorized a new share repurchase program (the \u201cProgram\u201d), under which the Company may repurchase American Depositary Shares (\u201cADSs\u201d), each representing one ordinary share of the Company, for an aggregate amount of\u00a0up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027.\u00a0BioNTech\u2019s disciplined approach to capital allocation and strong financial position enables this authorization.<\/p>\n<p align=\"justify\">BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The Program is designed to enhance capital efficiency, support long-term value creation and maintain financial flexibility\u00a0alongside BioNTech\u2019s objective to become a multi-product company by 2030.<\/p>\n<p align=\"justify\">The commencement, timing and total amount of ADS repurchases will depend upon market conditions and may be made in open market purchases from time to time, with a focus on price efficient repurchases to ensure prudent deployment of capital. BioNTech expects to fund the Program using its existing cash resources.<\/p>\n<p align=\"justify\">\u201cWe are confident in the Company\u2019s long-term growth prospects, and this share repurchase program is consistent with our capital allocation strategy and our commitment to sustainable value creation for our shareholders,\u201d\u00a0said <b>Ram\u00f3n Zapata, Chief Financial Officer at BioNTech. <\/b>\u201cAt the same time, our disciplined approach to capital deployment enables us to maintain the financial strength necessary to advance our innovative pipeline and aim for self-sustaining growth in the years ahead.\u201d<\/p>\n<p align=\"justify\">The Program has been designed to operate within the safe harbor provided by Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d), and the affirmative defense provided by Rule 10b5-1 of the Exchange Act.<\/p>\n<p align=\"justify\">\n        <b>About BioNTech<br \/><\/b>BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.<\/p>\n<p align=\"justify\">For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vgL8l_H2o-0rTzxwBzQeV1e6Xz8GxVmH4vGLlLVH8Xly4NlH-rDyaZu2ZWVLijYnarpqaHexgeeius8IjU_NGlatbp6Wz0wsadQ3wRDwuMagaoID_261MZUFBvw9T84oYBC6PUhGIAUgvZziK3j84IabpN0wpPtoWmD3XYUUgpu8bvvl60Pu7TdfbN3tIHuwTy11AjuWqG3ifLzwTcAA2-RpIaJFTKltxamwvVE5mMPDn4BK8WjA5Sh0zDYn3EU4_9MZrpAxhMIsIY-4-Gg12DWFmRGd2VcUbqn4aeL0IZA=\" rel=\"nofollow\" target=\"_blank\">www.BioNTech.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>BioNTech Forward-Looking Statements<\/b><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the Company\u2019s intent to repurchase, from time to time, the Company\u2019s ADSs. In some cases, forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.<br \/>The forward-looking statements in this press release are based on BioNTech\u2019s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech\u2019s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: changes in the market price of the Company\u2019s ADSs, general market conditions and applicable securities laws. <\/p>\n<p align=\"justify\">You should review the risks and uncertainties described under the heading \u201cRisk Factors\u201d in BioNTech\u2019s Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vgL8l_H2o-0rTzxwBzQeVxqCuhuWZ_PoYg4e6NZTjK_ms5XkPPvBhBpyE5n8V95X77wLL2eMEsBYTQ-y3uYTSg==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.\u00a0<\/p>\n<p>\n        <b>CONTACTS<\/b>\n      <\/p>\n<p>\n        <b>Investor Relations<\/b><br \/>\n        <br \/>Douglas Maffei, PhD <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h9jvm-w4MK2JaPtqLYaGuFwiVqT8czWTmUI8Ob1l4zLYXpFwg9v-sk0t4RekqWou8zhC9cUK-xqm9hD0kmZS6xPIfADWcqyxfoNAzQxbFtU=\" rel=\"nofollow\" target=\"_blank\">Investors@biontech.de<\/a><\/p>\n<p>\n        <b>Media Relations<\/b><br \/>\n        <br \/>Jasmina Alatovic<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OZP5rxy4QFHhs6A5JeNishlw3aZfBekuh4VmMjHmvZkWp4_uroV5c_9YZcV-ywC-RMj8zPYSBEKhmapDSohnhf8NXhklg0ws7vgqDjWatdU=\" rel=\"nofollow\" target=\"_blank\">Media@biontech.de<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NjQ1N2JlNGItNGZiNy00MTllLTkwZmItNGYxOTgzNjJjMWRhLTEwMTI1NTgtMjAyNi0wNS0wNy1lbg==\/tiny\/BioNTech-SE.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MAINZ, Germany,\u00a0May 7, 2026 (GLOBE NEWSWIRE) &#8212;\u00a0BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today announced that it has authorized a new share repurchase program (the \u201cProgram\u201d), under which the Company may repurchase American Depositary Shares (\u201cADSs\u201d), each representing one ordinary share of the Company, for an aggregate amount of\u00a0up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027.\u00a0BioNTech\u2019s disciplined approach to capital allocation and strong financial position enables this authorization. BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The Program is designed to enhance capital efficiency, support long-term value creation and maintain financial flexibility\u00a0alongside BioNTech\u2019s objective to become a multi-product company by 2030. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioNTech Announces New ADS Repurchase Program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-959516","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioNTech Announces New ADS Repurchase Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech Announces New ADS Repurchase Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MAINZ, Germany,\u00a0May 7, 2026 (GLOBE NEWSWIRE) &#8212;\u00a0BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today announced that it has authorized a new share repurchase program (the \u201cProgram\u201d), under which the Company may repurchase American Depositary Shares (\u201cADSs\u201d), each representing one ordinary share of the Company, for an aggregate amount of\u00a0up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027.\u00a0BioNTech\u2019s disciplined approach to capital allocation and strong financial position enables this authorization. BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The Program is designed to enhance capital efficiency, support long-term value creation and maintain financial flexibility\u00a0alongside BioNTech\u2019s objective to become a multi-product company by 2030. The &hellip; Continue reading &quot;BioNTech Announces New ADS Repurchase Program&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T10:48:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioNTech Announces New ADS Repurchase Program\",\"datePublished\":\"2026-05-07T10:48:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/\"},\"wordCount\":707,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/\",\"name\":\"BioNTech Announces New ADS Repurchase Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ==\",\"datePublished\":\"2026-05-07T10:48:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-new-ads-repurchase-program-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech Announces New ADS Repurchase Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioNTech Announces New ADS Repurchase Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/","og_locale":"en_US","og_type":"article","og_title":"BioNTech Announces New ADS Repurchase Program - Market Newsdesk","og_description":"MAINZ, Germany,\u00a0May 7, 2026 (GLOBE NEWSWIRE) &#8212;\u00a0BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today announced that it has authorized a new share repurchase program (the \u201cProgram\u201d), under which the Company may repurchase American Depositary Shares (\u201cADSs\u201d), each representing one ordinary share of the Company, for an aggregate amount of\u00a0up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027.\u00a0BioNTech\u2019s disciplined approach to capital allocation and strong financial position enables this authorization. BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The Program is designed to enhance capital efficiency, support long-term value creation and maintain financial flexibility\u00a0alongside BioNTech\u2019s objective to become a multi-product company by 2030. The &hellip; Continue reading \"BioNTech Announces New ADS Repurchase Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-07T10:48:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioNTech Announces New ADS Repurchase Program","datePublished":"2026-05-07T10:48:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/"},"wordCount":707,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/","name":"BioNTech Announces New ADS Repurchase Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ==","datePublished":"2026-05-07T10:48:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MDU1MyM0MDIzODgzNDUjMjAwMDk4NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-new-ads-repurchase-program-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioNTech Announces New ADS Repurchase Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=959516"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959516\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=959516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=959516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=959516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}